• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of pnasPNASInfo for AuthorsSubscriptionsAboutThis Article
Proc Natl Acad Sci U S A. Dec 5, 1995; 92(25): 11490–11494.
PMCID: PMC40427

Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity.

Abstract

Group B streptococci (GBS) cause sepsis and meningitis in neonates and serious infections in adults with underlying chronic illnesses. Specific antibodies have been shown to be an important factor in protective immunity for neonates, but the role of serum complement is less well defined. To elucidate the function of the complement system in immunity to this pathogen, we have used the approach of gene targeting in embryonic stem cells to generate mice totally deficient in complement component C3. Comparison of C3-deficient mice with mice deficient in complement component C4 demonstrated that the 50% lethal dose for GBS infection was reduced by approximately 50-fold and 25-fold, respectively, compared to control mice. GBS were effectively killed in vitro by human blood leukocytes in the presence of specific antibody and C4-deficient serum but not C3-deficient serum. The defective opsonization by C3-deficient serum in vitro was corroborated by in vivo studies in which passive immunization of pregnant dams with specific antibodies conferred protection from GBS challenge to normal and C4-deficient pups but not C3-deficient pups. These results indicate that the alternative pathway is sufficient to mediate effective opsonophagocytosis and protective immunity to GBS in the presence of specific antibody. In contrast, the increased susceptibility to infection of non-immune mice deficient in either C3 or C4 implies that the classical pathway plays an essential role in host defense against GBS infection in the absence of specific immunity.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.2M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Click on the image to see a larger version.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ. 1992 Nov 20;41(6):25–32. [PubMed]
  • Schwartz B, Schuchat A, Oxtoby MJ, Cochi SL, Hightower A, Broome CV. Invasive group B streptococcal disease in adults. A population-based study in metropolitan Atlanta. JAMA. 1991 Aug 28;266(8):1112–1114. [PubMed]
  • Farley MM, Harvey RC, Stull T, Smith JD, Schuchat A, Wenger JD, Stephens DS. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med. 1993 Jun 24;328(25):1807–1811. [PubMed]
  • Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med. 1976 Apr 1;294(14):753–756. [PubMed]
  • Baker CJ, Edwards MS, Kasper DL. Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection. Pediatrics. 1981 Oct;68(4):544–549. [PubMed]
  • Kasper DL, Baker CJ, Baltimore RS, Crabb JH, Schiffman G, Jennings HJ. Immunodeterminant specificity of human immunity to type III group B streptococcus. J Exp Med. 1979 Feb 1;149(2):327–339. [PMC free article] [PubMed]
  • Baltimore RS, Baker CJ, Kasper DL. Antibody to group B Streptococcus type III in human sera measured by a mouse protection test. Infect Immun. 1981 Apr;32(1):56–61. [PMC free article] [PubMed]
  • Wessels MR, Paoletti LC, Kasper DL, DiFabio JL, Michon F, Holme K, Jennings HJ. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus. J Clin Invest. 1990 Nov;86(5):1428–1433. [PMC free article] [PubMed]
  • Paoletti LC, Wessels MR, Rodewald AK, Shroff AA, Jennings HJ, Kasper DL. Neonatal mouse protection against infection with multiple group B streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1994 Aug;62(8):3236–3243. [PMC free article] [PubMed]
  • Shigeoka AO, Jensen CL, Pincus SH, Hill HR. Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci. J Infect Dis. 1984 Jul;150(1):63–70. [PubMed]
  • Edwards MS, Nicholson-Weller A, Baker CJ, Kasper DL. The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of type III, group B Streptococcus. J Exp Med. 1980 May 1;151(5):1275–1287. [PMC free article] [PubMed]
  • Johnston RB, Jr, Klemperer MR, Alper CA, Rosen FS. The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors. J Exp Med. 1969 Jun 1;129(6):1275–1290. [PMC free article] [PubMed]
  • Schuchat A, Oxtoby M, Cochi S, Sikes RK, Hightower A, Plikaytis B, Broome CV. Population-based risk factors for neonatal group B streptococcal disease: results of a cohort study in metropolitan Atlanta. J Infect Dis. 1990 Sep;162(3):672–677. [PubMed]
  • Gotoff SP, Odell C, Papierniak CK, Klegerman ME, Boyer KM. Human IgG antibody to group b Streptococcus type III: comparison of protective levels in a murine model with levels in infected human neonates. J Infect Dis. 1986 Mar;153(3):511–519. [PubMed]
  • Gray BM, Pritchard DG, Dillon HC., Jr Seroepidemiology of group B streptococcus type III colonization at delivery. J Infect Dis. 1989 Jun;159(6):1139–1142. [PubMed]
  • Anderson DC, Freeman KL, Heerdt B, Hughes BJ, Jack RM, Smith CW. Abnormal stimulated adherence of neonatal granulocytes: impaired induction of surface Mac-1 by chemotactic factors or secretagogues. Blood. 1987 Sep;70(3):740–750. [PubMed]
  • Bruce MC, Baley JE, Medvik KA, Berger M. Impaired surface membrane expression of C3bi but not C3b receptors on neonatal neutrophils. Pediatr Res. 1987 Mar;21(3):306–311. [PubMed]
  • Smith JB, Campbell DE, Ludomirsky A, Polin RA, Douglas SD, Garty BZ, Harris MC. Expression of the complement receptors CR1 and CR3 and the type III Fc gamma receptor on neutrophils from newborn infants and from fetuses with Rh disease. Pediatr Res. 1990 Aug;28(2):120–126. [PubMed]
  • Baker CJ, Edwards MS, Webb BJ, Kasper DL. Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus. J Clin Invest. 1982 Feb;69(2):394–404. [PMC free article] [PubMed]
  • Eads ME, Levy NJ, Kasper DL, Baker CJ, Nicholson-Weller A. Antibody-independent activation of C1 by type Ia group B streptococci. J Infect Dis. 1982 Nov;146(5):665–672. [PubMed]
  • Lundwall A, Wetsel RA, Domdey H, Tack BF, Fey GH. Structure of murine complement component C3. I. Nucleotide sequence of cloned complementary and genomic DNA coding for the beta chain. J Biol Chem. 1984 Nov 25;259(22):13851–13856. [PubMed]
  • Lee KF, Li E, Huber LJ, Landis SC, Sharpe AH, Chao MV, Jaenisch R. Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell. 1992 May 29;69(5):737–749. [PubMed]
  • Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975 Nov 5;98(3):503–517. [PubMed]
  • Marques MB, Kasper DL, Pangburn MK, Wessels MR. Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III group B streptococci. Infect Immun. 1992 Oct;60(10):3986–3993. [PMC free article] [PubMed]
  • Baltimore RS, Kasper DL, Baker CJ, Goroff DK. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol. 1977 Feb;118(2):673–678. [PubMed]
  • Rodewald AK, Onderdonk AB, Warren HB, Kasper DL. Neonatal mouse model of group B streptococcal infection. J Infect Dis. 1992 Sep;166(3):635–639. [PubMed]
  • Edwards MS, Kasper DL, Jennings HJ, Baker CJ, Nicholson-Weller A. Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci. J Immunol. 1982 Mar;128(3):1278–1283. [PubMed]
  • Wessels MR, Paoletti LC, Rodewald AK, Michon F, DiFabio J, Jennings HJ, Kasper DL. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect Immun. 1993 Nov;61(11):4760–4766. [PMC free article] [PubMed]
  • Fearon DT. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971–1975. [PMC free article] [PubMed]
  • Pangburn MK, Müller-Eberhard HJ. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci U S A. 1978 May;75(5):2416–2420. [PMC free article] [PubMed]
  • Wessels MR, Haft RF, Heggen LM, Rubens CE. Identification of a genetic locus essential for capsule sialylation in type III group B streptococci. Infect Immun. 1992 Feb;60(2):392–400. [PMC free article] [PubMed]
  • Brown EJ, Hosea SW, Hammer CH, Burch CG, Frank MM. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J Clin Invest. 1982 Jan;69(1):85–98. [PMC free article] [PubMed]
  • Verhoef J, Peterson P, Kim Y, Sabath LD, Quie PG. Opsonic requirements for staphylococcal phagocytosis. Heterogeneity among strains. Immunology. 1977 Aug;33(2):191–197. [PMC free article] [PubMed]
  • Bjornson AB, Bjornson HS. Participation of immunoglobulin and the alternative complement pathway in opsonization of Bacteroides fragilis and Bacteroides thetaiotaomicron. J Infect Dis. 1978 Sep;138(3):351–358. [PubMed]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...